Kiniksa Pharmaceuticals International (KNSA) Cash from Investing Activities (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 10 years of Cash from Investing Activities data on file, last reported at -$73.6 million in Q2 2026.

• Quarterly Cash from Investing Activities fell 1794.93% year-over-year to -$73.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$239.1 million (down 6889.69% YoY) and the FY2025 annual result came in at -$189.0 million, down 601.68% from the prior year.
• Cash from Investing Activities retreated to -$73.6 million in Q2 2026, from -$31.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $65.3 million in Q4 2024 to a low of -$73.6 million in Q2 2026.
• A 5-year average of -$16.4 million and a median of -$18.8 million in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities jumped 538.38% — and 2026, when it plunged 1794.93%.
• Tracing KNSA's Cash from Investing Activities over 5 years: stood at -$42.7 million in 2022, then jumped by 65.09% to -$14.9 million in 2023, then jumped by 538.38% to $65.3 million in 2024, then slumped by 208.46% to -$70.8 million in 2025, then dropped by 3.91% to -$73.6 million in 2026.
• The last three Cash from Investing Activities figures came in at -$73.6 million (Q2 2026), -$31.9 million (Q1 2026), and -$70.8 million (Q4 2025), per Business Quant data.